Cubicin

/ MSD

Administration Duration: CUBICIN should be administered intravenously either by injection over a two minute period or by infusion over a thirty minute period.
Complicated Skin and Skin Structure Infections: CUBICIN 4 mg/kg should be administered intravenously in 0.9% sodium chloride injection once every 24 hours for 7 to 14 days.
Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates: CUBICIN 6 mg/kg should be administered intravenously in 0.9% sodium chloride injection once every 24 hours for 2 to 6 weeks. There are limited safety data for the use of CUBICIN for more than 28 days of therapy. In the Phase 3 trial, there were a total of 14 patients who were treated with CUBICIN for more than 28 days.
Patients with Renal Impairment: The recommended dosage regimen for patients with creatinine clearance (CLCR) less than 30 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), is 4 mg/kg (cSSSI) or 6 mg/kg (S. aureus bloodstream infections) once every 48 hours (See prescribing information for full details).
When possible, CUBICIN should be administered following the completion of
hemodialysis on hemodialysis days.
See prescribing information for full details.

Complicated Skin and Skin Structure Infections: Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant
isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).
Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates: Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided
infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.
Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram negative or anaerobic organism.

Known hypersensitivity to daptomycin.

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including daptomycin, and may range in severity from mild to life-threatening. Therefore it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of any antibacterial agent. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicated that a toxin produced by ‘Clostridium difficile’ is a primary cause of

See prescribing information for full details.